当前位置： SCI文献检索 > ENDOCRINOLOGY期刊下所有文献 > ERα-targeted therapy in ovarian cancer cells by a novel estradiol-platinum(II) hybrid.

ERα-targeted therapy in ovarian cancer cells by a novel estradiol-platinum(II) hybrid.

Abstract：

:As we previously showed, we have synthesized a new family of 17β-estradiol-platinum(II) hybrids. Earlier studies revealed the VP-128 hybrid to show high efficiency compared with cisplatin toward hormone-dependent breast cancer cells. In the present research, we have studied the antitumor activity of VP-128 in vitro and in vivo against ovarian cancer. In nude mice with ovarian xenografts, VP-128 displayed selective activity toward hormone-dependent tumors and showed higher efficiency than cisplatin to inhibit tumor growth. Similarly, in vitro, transient transfection of estrogen receptor (ER)-α in ERα-negative A2780 cells increased their sensitivity to VP-128-induced apoptosis, confirming the selectivity of VP-128 toward hormone-dependent tumor cells. In agreement, Western blot analysis revealed that VP-128 induced higher caspase-9, caspase-3, and poly (ADP-ribose) polymerase cleavage compared with cisplatin. The activation of caspase-independent apoptosis was also observed in ERα-negative A2780 cells, in which VP-128 rapidly induced the translocation of apoptosis-inducing factor to the nucleus. Conversely, subcellular localization of apoptosis-inducing factor was not modified in ERα-positive Ovcar-3 cells. We also discovered that VP-128 induces autophagy in ovarian cancer cells because of the formation of acidic vesicular organelles (AVOs) and increase of Light Chain 3B-II protein responsible for the formation of autophagosomes; pathways related to autophagy (AKT and mammalian target of rapamycin) were also down-regulated, supporting this mechanism. Finally, the inhibition of autophagy using chloroquine increased VP-128 efficiency, indicating a possible combination therapy. Altogether these results highlight the beneficial value of VP-128 for the treatment of hormone-dependent ovarian cancers and provide preliminary proof of concept for the efficient targeting of ERα- by 17β-estradiol-Pt(II)-linked chemotherapeutic hybrids in these tumors.

journal_name

Endocrinology

journal_title

Endocrinology

authors

Brasseur K,Leblanc V,Fabi F,Parent S,Descôteaux C,Bérubé G,Asselin E

doi

10.1210/en.2013-1083

subject

Has Abstract

pub_date

2013-07-01 00:00:00

pages

2281-95

issue

eissn

0013-7227

issn

1945-7170

pii

en.2013-1083

journal_volume

154

pub_type

杂志文章

在线工具

ERα-targeted therapy in ovarian cancer cells by a novel estradiol-platinum(II) hybrid.